Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Health Research topic
No spam. Unsubscribe anytime.
House committee backs bill to help attract early‑phase clinical trials to Louisiana
Summary
The committee voted to report HB 1223, which establishes an LED‑led framework to market Louisiana for early‑phase clinical trials, adds procedural safeguards and explicitly preserves local IRB authority and patient privacy.
Representative McFarland told the committee HB 1223 is designed to strengthen Louisiana’s ability to host early‑phase clinical trials by providing a statewide framework and marketing support from Louisiana Economic Development (LED). He emphasized the bill does not regulate research or alter clinical decision‑making and that amendments (3,965) added protections for patient privacy and clarified that LED is not an approval body.
The sponsor and supporters said the measure aims to reduce duplication of institutional review processes, improve coordination among hospitals and universities, and help recruit sponsor‑driven trials that bring new treatments and economic activity. Committee members pressed about funding and institutional independence; McFarland said the bill does not ask LED for dedicated appropriations and that participation by research entities remains voluntary. After discussion the committee adopted the amendment package and reported HB 1223 favorable.
